Progress Toward Hepatitis B Control and Elimination of Mother-to-Child Transmission of Hepatitis B Virus — World Health Organization African Region, 2016–2021

Chronic hepatitis B virus (HBV) infection is one of the leading causes of cirrhosis and liver cancer. In 2019, approximately 1.5 million persons newly acquired chronic HBV infection; among these, 990,000 (66%) were in the World Health Organization (WHO) African Region (AFR). Most chronic HBV infections are acquired through mother-to-child transmission (MTCT) or during early childhood, and approximately two thirds of these infections occur in AFR. In 2016, the World Health Assembly endorsed the goal of elimination of mother-to-child transmission (EMTCT) of HBV, documented by ≥90% coverage with both a timely hepatitis B vaccine (HepB) birth dose (HepB-BD) and 3 infant doses of HepB (HepB3), and ≤0.1% hepatitis B surface antigen (HBsAg) seroprevalence among children aged ≤5 years. In 2016, the WHO African Regional Committee endorsed targets for a 30% reduction in incidence (≤2% HBsAg seroprevalence in children aged ≤5 years) and ≥90% HepB3 coverage by 2020. By 2021, all 47 countries in the region provided HepB3 to infants beginning at age 6 weeks, and 14 countries (30%) provided HepB-BD. By December 2021, 16 (34%) countries achieved ≥90% HepB3 coverage, and only two (4%) achieved ≥90% timely HepB-BD coverage. Eight countries (17%) conducted nationwide serosurveys among children born after the introduction of HepB to assess HBsAg seroprevalence: six countries had achieved ≤2% seroprevalence, but none had achieved ≤0.1% seroprevalence among children. The development of immunization recovery plans following the COVID-19 pandemic provides an opportunity to accelerate progress toward hepatitis B control and EMTCT, including introducing HepB-BD and increasing coverage with timely HepB-BD and HepB3 vaccination. Representative HBsAg serosurveys among children and a regional verification body for EMTCT of HBV will be needed to monitor progress.


Introduction
In 2019, approximately 1.5 million persons newly acquired chronic hepatitis B virus (HBV) infection; among these, 990,000 (66%) were in the World Health Organization (WHO) African Region (AFR)* (1). Because most chronic HBV infections are acquired through mother-to-child transmission (MTCT) or during early childhood (2), WHO recommends that all newborns receive a dose of hepatitis B vaccine (HepB) within 24 hours of birth (hepatitis B vaccine birth dose [HepB-BD]) followed by 2 or 3 doses † of HepB during the first year of life (2). In 2016, the World Health Assembly endorsed the goal of eliminating viral hepatitis as a public health threat by 2030, including the elimination of mother-to-child transmission (EMTCT) of HBV, documented by demonstration of ≥90% coverage with both a timely § HepB-BD and 3 doses of HepB (HepB3), and ≤0.1% hepatitis B surface antigen (HBsAg) ¶ seroprevalence among children aged ≤5 years (3). In 2016, the WHO African Regional Committee endorsed two targets for hepatitis B control: 1) 30% reduction in incidence (equating to HBsAg prevalence of ≤2% in children aged ≤5 years), and 2) ≥90% HepB3 coverage by 2020. In 2021, AFR countries endorsed a call to develop strategies for elimination of MTCT of HBV, including increasing HepB-BD and HepB3 coverage and improving access to antenatal care and quality delivery services (4,5). This report describes progress made during 2016-2021 to achieve hepatitis B control and elimination of MTCT of HBV in AFR.

Methods
Information on country immunization activities was obtained by review of administrative** or official † † HepB coverage data reported to WHO and UNICEF that generate annual country vaccination coverage estimates. To identify HBsAg seroprevalence surveys conducted in AFR, a MEDLINE literature review was conducted using the following search criteria (Afro country names), and ("hepatitis B" OR "HBV") AND (

HBsAg Seroprevalence Surveys
Because most chronic HBV infections (particularly those among young children) are asymptomatic, the impact of hepatitis B vaccination is usually measured by HBsAg seroprevalence among children born after the introduction of HepB, usually those aged ≤5 years*** (3,6). During 2016-2021, HBsAg seroprevalence surveys among children were conducted at national or regional levels in eight (17%) countries.  (1). HBsAg seroprevalence among women of reproductive age or pregnant women provides an estimate of the risk for MTCT of HBV. Data from population-based HBsAg surveys among women of reproductive age or from screening of pregnant women available from 11 countries showed HBsAg seroprevalences ranging from 1.2% (Rwanda) to 9.8% (Sierra Leone) ( Table 2).

Elimination of Mother-to-Child Transmission of HBV
By December 2021, although 21 (45%) AFR countries had developed a plan for EMTCT of HIV, syphilis, and HBV, only six countries † † † reported having implemented the EMTCT guidelines for routine HBsAg testing of pregnant women, provision of antiviral medications to eligible (HBsAg-seropositive) women, § § § and administration of HepB-BD to newborns. As of December 2021, ≥90% of pregnant women in 29 (62%) AFR countries had at least one antenatal care visit (Table 3). Data from the most recent nationwide surveys showed that in 37 (79%) countries, approximately one half of women gave birth in health care facilities, and in 23 (49%) countries, ≥80% of women delivered in a health facility (Table 1). To acknowledge progress toward EMTCT of HBV in countries with high endemicity, WHO developed a certification mechanism for the path to elimination of MTCT of HBV, using three tiers (bronze, silver, and gold) indicating increasing levels of progress ¶ ¶ ¶ (6). Based on HepB immunization interventions in 2021, Botswana might be eligible for the bronze tier, three countries (Namibia, Sao Tome and Principe, and Senegal) might be eligible for the silver tier, and two countries (Algeria and Cabo Verde) might be eligible for the gold tier certification (

Discussion
All 47 AFR countries have had HepB in their infant immunization schedule since 2014, and 16 (34%) have achieved ≥90% HepB3 coverage for ≥2 years, including four countries that documented <2% HBsAg seroprevalence in children, consistent with hepatitis B control. The COVID-19 pandemic led to disruptions in immunization services,**** resulting in fewer AFR countries attaining ≥90% HepB3 coverage, declining from a peak of 20 (43%) in 2018 to 16 (34%) in 2021. Strategies to recover and strengthen immunization programs of 35 countries by 2025 (5) would require six to seven countries to introduce HepB-BD each year. Following introduction, delivery in health facilities by skilled workers was shown to be significantly correlated with timely HepB-BD administration (9). Promoting and enabling delivery in health facilities, training health care workers, and integrating HepB-BD vaccination into newborn care, are essential to increasing timely HepB-BD coverage in AFR.
In addition to providing timely HepB-BD and HepB3, the identification of pregnant women with HBV infection and provision of antiviral medications for those who are eligible for treatment would further advance EMTCT of HBV (9,10). However, as of 2021, only 17 (36%) AFR countries had national policies for antenatal HBsAg testing and treatment, and nationally representative serosurveys in AFR were uncommon. HBsAg seroprevalence surveys would help document progress and guide policy decisions regarding hepatitis B control and elimination in the region.

Limitations
The findings in this report are subject to at least two limitations. First, HepB-BD coverage data were not consistently reported by five countries,***** which might have resulted in the underestimation of overall HepB-BD regional coverage. Second, assessment of hepatitis B control and EMTCT is challenging in countries that have introduced HepB-BD and achieved high coverage with HepB3, because nationally representative seroprevalence surveys to estimate the prevalence of HBV infection among children are lacking in those countries.

Implications for Public Health Practice
Establishing a regional verification mechanism for hepatitis B control and EMTCT of HBV could elevate the profile of elimination initiatives in AFR. Scaling up the introduction of HepB-BD and strategies to increase timely HepB-BD and HepB3 coverage would accelerate the reduction of preventable hepatitis B-associated morbidity and mortality and progress toward 2030 hepatitis B elimination goals.